TY  - JOUR

T1  - A phase II/III, double -blind, randomised trial comparing maintenance lapatinib versus placebo after first line chemotherapy in HER1/2 positive metastatic cancer patients.

JO  - Journal of Clinical Oncology

PY  - 2017/01/01

AU  - Powles T

AU  - Huddart RA

AU  - Elliott T

AU  - Sarker S-J

AU  - Ackerman C

AU  - Jones R

AU  - Hussain S

AU  - Crabb S

AU  - Jagdev S

AU  - Chester J

AU  - Hilman S et al

ED  - 

DO  - DOI: 10.1200/jco.2015.66.3468

PB  - American Society of Clinical Oncology

VL  - 35

IS  - 1

SP  - 48

EP  - 55

Y2  - 2024/12/22

ER  -